DLL3-Targeted ADC ZL-1310 Shows Early Promise in Neuroendocrine Carcinomas

Early-phase data from the ZL-1310-002 trial introduce a potentially important new therapeutic option for patients with advanced neuroendocrine carcinomas (NECs), a group of aggressive malignancies with very limited treatment options after platinum-based chemotherapy. Among these, neuroendocrine prostate cancer (NEPC) represents one of the most clinically challenging subtypes, characterized by rapid progression, resistance to androgen receptor–targeted therapies, and poor survival outcomes.

ZL-1310 is a novel antibody-drug conjugate targeting delta-like ligand 3 (DLL3), a protein broadly expressed across neuroendocrine tumors and largely absent in normal tissues. This makes DLL3 an attractive therapeutic target, particularly in NEPC where lineage plasticity drives the transition from adenocarcinoma to an androgen-independent neuroendocrine phenotype. The drug combines a DLL3-directed monoclonal antibody with a topoisomerase I inhibitor payload, delivered through a tumor microenvironment–activatable linker designed to enhance selective drug release within tumor tissue.

In this Phase 1b study, patients with metastatic NECs who had progressed after platinum chemotherapy received ZL-1310 at 1.6 mg/kg every three weeks. Although the cohort was small and heterogeneous, the inclusion of patients with NEPC provides an early signal of activity in a disease setting where no standard second-line therapy exists. Historically, outcomes in NEPC after platinum failure are dismal, with response rates typically below 20% and progression-free survival often measured in just a few months.

The reported objective response rate of 48% among evaluable patients is therefore striking, even at this early stage. Notably, responses were observed despite prior exposure to DLL3-targeted therapy in at least one patient, suggesting that ZL-1310 may overcome some mechanisms of resistance associated with earlier DLL3-directed approaches. While only a small fraction of the study population had NEPC, the biology of DLL3 expression in prostate neuroendocrine tumors supports the relevance of this target in that subgroup. DLL3 is frequently upregulated in treatment-emergent NEPC, often alongside key genomic alterations such as RB1 and TP53 loss, reinforcing its role as both a biomarker and a therapeutic vulnerability.

The safety profile appears manageable, with relatively low rates of high-grade adverse events. The most common toxicities (anemia, nausea, and vomiting) are consistent with the topoisomerase I inhibitor class.

Source.